Windgap Medical

Windgap Medical: Injecting Simplicity Into Complex Drug Delivery

Antonette Ho2024-02-17T17:48:14-05:00Injectable formulations are the fastest growing segment in the pharmaceutical industry. According to Precedence Research, the global injectable drug delivery market reached U.S. $561 billion in 2021 and is expected to surpass $1,224 billion by 2030. Given the astounding 40-70% of patients in the US who are noncompliant with their drug regimens, any simplification of administration is a win for patients, caregivers, providers and society at large.5 Recognizing this need, along with the demand for improved patient experience and desire...

Windgap Medical Appoints Aaron Mann as CEO, Michael Samar as CFO

Antonette Ho2023-02-20T12:34:57-05:00Windgap Medical announced today it has appointed Aaron Mann as the company's Chief Executive Officer and Michael Samar as the company's Chief Financial Officer, effective February 1. Both bring significant industry tenure and experience to their roles, and with Windgap Co-Founder Brent Buchine, will lead the company's continued growth in the field of complex injectable drug delivery solutions. "Aaron Mann brings a depth of industry experience that is a strong complement to the scientific and technical team in place today...

Windgap Medical, Inc. Closes Over $39 Million of Series B-1 Investment, More Than Twenty Percent Over Its Initial Goal

Ziad2022-11-25T13:59:58-05:00Windgap Medical, Inc., a leading specialty pharmaceutical and drug delivery platform company, announced today that it has successfully completed its final close with over $39 million of Series B-1 equity financing, led by Taiwania Capital. This equity round of investment expanded beyond an initial target of approximately $32 million due to strong investor interest. This equity financing is also supported by existing investors, including Shepherd Kaplan Krochuk (SKK) and Molex Ventures (a Koch Industries company), along with new investors including...

VC funding update: Which Boston startups made bank in September

Ziad2022-11-25T14:00:11-05:00Boston's startups and tech companies were busy in September, pulling in collective billions from VCs and other investors. Here's who raised and what they pulled in: Watertown-based pharmaceutical company Windgap Medical Inc. raised more than $17M in equity. Read more >>

Taiwania Capital Joins Pool of Existing Investors to Fund $17 Million of Series B-1 Investment in Novel Drug Delivery Company, Windgap Medical, Inc.

Ziad2022-11-25T14:00:12-05:00 Windgap Medical, Inc., a leading drug delivery platform company, announced today that it has successfully completed initial closing of over $17 million of Series B-1 equity financing round of investment, led by Taiwania Capital. This equity investment round is also supported by existing investors, including Shepherd Kaplan Krochuk, Molex Ventures (a Koch Industries company), and others. Read more >>

University of Minnesota Twin Cities and Windgap Medical receive $3.2 million NIH grant to develop cyanide antidote autoinjector

Ziad2022-11-25T14:02:39-05:00 The University of Minnesota Twin Cities and Windgap Medical have received a $3.2 million grant from the National Institutes of Health (NIH) to develop a new device to quickly administer a recently developed antidote for cyanide poisoning. Under the grant, researchers from the University’s Center for Drug Design, College of Pharmacy, and Massachusetts-based pharmaceutical company Windgap Medical are collaborating to design an autoinjector. Read more >>

ALK announces new epinephrine auto-injector strategy based on innovative new product for the USA

Ziad2022-11-25T14:03:27-05:00 ALK today announced that it has finalised its strategy for entering the US market for epinephrine (adrenaline) auto-injectors (EAIs) and that this will focus on a next-generation EAI in partnership with US-based Windgap Medical. Read more >>

Local company making strides toward longer-lasting EpiPen alternative

Ziad2022-11-25T14:03:27-05:00 It's that time of year again when some parents go on the hunt for an elusive pharmaceutical product. Once again, epinephrine injectable pens — or EpiPens — are in short supply, but a local company is making steady strides toward a possible solution. Read more >>

Windgap Medical Announces Strategic Investment from Molex Ventures

Ziad2022-11-25T14:03:39-05:00 Windgap Medical, Inc. announced today that it has finalized a deal to enable a strategic investment from Molex Ventures, LLC, a subsidiary of Koch Industries ("Molex Ventures").  Molex Ventures will be investing into an investment round in Windgap led by the Boston-based firm of Shepherd Kaplan Krochuck, LLC.  Read more >>

Local company developing EpiPen alternative that would last longer

Ziad2022-11-25T14:03:39-05:00 Those who rely on lifesaving injectable epinephrine pens, known by the brand name EpiPens, know the expensive often go unused and expire. Now, a local company is developing an innovative injector that patients can hang on to longer that could also save them money. Read more >>